Latest news with #SolarEclipse
Yahoo
15-05-2025
- Business
- Yahoo
Popular Local Denver Brewery is Closing After 8 Years
A beloved Denver, Colorado brewery is shutting down its doors at the end of the month. On Tuesday, Burns Family Artisan Ales, which first opened in August 2018 under the guidance of award-winning brewer Wayne Burns, will close its taproom to the public at the end of the month. "The fire is going out. Burns Family Artisan Ales' last day selling beer through the taproom to the public will be May 31, 2025," Burns and his wife, co-owner Laura Worley, shared on Facebook. In its tenure, Burns Family Artisan Ales not only built up a strong customer base, but also won medals at the Great American Beer Festival. For his career, Burns has captured four medals at the competition. "We developed classic and experimental styles from 2.2%abv to 25.1%abv," said the Burns Family post. "We succeeded with our niche of barrel-aged and high-alcohol beer to an extent that we remain the 4th highest rated brewery in the state of Colorado and consistently rate within the top ten breweries nationwide for our Solar Eclipse series. We have a client base of loyalists who visit us regularly, cheerlead for us, promote us and can't say enough good things about us (thank you!)." Despite all of the accomplishments and the strong reputation, Burns Family Artisan Ales sadly could not escape the harsh reality of insufficient sales. "So, why leave what is seemingly a great run? It is certain that specious speculation will conjure up many reasons, and we implore you to seek the truth rather than believe in rumor," Burns and Worley explained. "The truth of the matter is that our taproom was full only on the rarest of occasions. We needed more patrons. The most advantageous way to get the best cash flow is by selling someone a glass of beer, in your own place, over the bar. We simply didn't have enough people visiting to enable growth." The owners went on to say it wasn't the fault of them or their customers for the situation, but it's "just the way business can be." If you're planning to visit the Burns taproom before it closes, you can find the company's official website here.
Miami Herald
06-05-2025
- Business
- Miami Herald
SafeHeal(R) Closes Oversubscribed €35 Million Series C Equity Financing
Press Releases SafeHeal(R) Closes Oversubscribed €35 Million Series C Equity Financing Financing led by Solar Eclipse with new investors Gideon Strategic Partners and M&L Healthcare, part of M&L Group, and returning investors Sofinnova Partners and one of the largest Multinational life sciences corporations from a strategic standpoint. Proceeds will support the completion of SafeHeal's IDE pivotal study and preparation for commercial launch of their lead technology, Colovac®. SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced a successful completion of an oversubscribed €35 million Series C equity financing to validate the use of Colovac®, a groundbreaking temporary endoluminal fecal bypass system. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection. The proceeds leave SafeHeal well-funded to complete its IDE Pivotal study and accelerate preparation for commercial launch of their lead technology, Colovac. In conjunction with the financing, Martin Sands and Steven Sands of Solar Eclipse will join as board member and observer respectively. The Colovac endoluminal bypass system is a less-invasive alternative to temporary diverting ostomy, the current standard of care for patients undergoing colorectal resection. Diverting ostomy is applied prophylactically to most patients today undergoing a low anterior resection (LAR) and anastomosis. The ostomy temporarily diverts the stool away from the healing anastomosis to the outside of the body and into an ostomy bag. In most cases, the ostomy is needed only until the anastomosis has healed, and then it can be reversed, typically after 2-6 months. The eventual reversal of the ostomy requires another operation, with a second hospital stay, recovery period and associated complications. In some cases, the ostomy may not be reversed and becomes permanent. In addition to the potential surgical complications associated with ostomy procedures, patients may experience an impact to their quality of life due to social isolation, reduced physical activity and/or intimacy. Colovac is an alternative to diverting ostomy, designed to eliminate the need for a temporary stoma in most patients. It aims to improve patient recovery and quality of life by eliminating stoma related complications including permanent stoma and eliminating the physical and emotional burden associated with stoma management and care. Colovac has been successfully studied in over 100 patients in the U.S., Europe, and Asia and has received FDA Breakthrough Designation status. "This is a very exciting time at SafeHeal as we continue to achieve a number of critical value-creating milestones in the coming months," said Chris Richardson, President and Chief Executive Officer. "We are grateful for the continuing support from Sofinnova Partners and delighted to welcome Solar Eclipse, Gideon and M&L Healthcare, part of M&L Group as new investors. This capital raise places SafeHeal in an excellent position to continue our momentum toward FDA approval and commercialization of Colovac." Chris Richardson, President & CEO, SafeHeal "The current standard of care for treatment of Colon Resection is associated with significant morbidity, risk of permanent stoma and reduced quality of life, driving both the clinical community and regulators to search for better treatment options. SafeHeal is addressing this significant unmet medical need with a highly novel approach," said Martin Sands of Solar Eclipse. "I believe SafeHeal's therapeutic platform will dramatically improve quality of life and outcomes for patients with Colon Resections. I look forward to supporting the team to achieve multiple key milestones over the next 18 months." "We've been with SafeHeal since day one, when it was born out of our Medtech accelerator, MDStart. Our continued support in this Series C reflects a deep growing belief in their potential to revolutionize care for patients facing ostomy," said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. ABOUT SAFEHEAL® SafeHeal SAS, headquartered in Paris, France, and its wholly owned U.S. subsidiary, SafeHeal Inc., is a clinical-stage medical device company developing Colovac, a device intended as an alternative to diverting ostomy in patients undergoing colorectal surgery. Colovac is a flexible endoluminal bypass sheath designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for 7-10 days, until the body's natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure. Colovac is an investigational device, not currently available for sale. For more information, please visit MEDIA CONTACTS USA Scott DePierro Vice President U.S. Operations and Global Business Development, SafeHeal 203-444-0279 sdepierro@ Europe: Karl-Heinz Blohm Vice President, International, SafeHeal +33 (0) 6 5181 7895 kblohm@ ### SOURCE: SafeHeal This story was originally published May 6, 2025 at 8:06 AM.
Associated Press
06-05-2025
- Health
- Associated Press
SafeHeal® Closes Oversubscribed €35 Million Series C Equity Financing
NEW YORK, NY, UNITED STATES, May 6, 2025 / / -- Financing led by Solar Eclipse with new investors Gideon Strategic Partners and M&L Healthcare, part of M&L Group, and returning investors Sofinnova Partners and one of the largest Multinational life sciences corporations from a strategic standpoint. Proceeds will support the completion of SafeHeal's IDE pivotal study and preparation for commercial launch of their lead technology , Colovac®. SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced a successful completion of an oversubscribed €35 million Series C equity financing to validate the use of Colovac®, a groundbreaking temporary endoluminal fecal bypass system. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection. The proceeds leave SafeHeal well-funded to complete its IDE Pivotal study and accelerate preparation for commercial launch of their lead technology, Colovac. In conjunction with the financing, Martin Sands and Steven Sands of Solar Eclipse will join as board member and observer respectively. The Colovac endoluminal bypass system is a less-invasive alternative to temporary diverting ostomy, the current standard of care for patients undergoing colorectal resection. Diverting ostomy is applied prophylactically to most patients today undergoing a low anterior resection (LAR) and anastomosis. The ostomy temporarily diverts the stool away from the healing anastomosis to the outside of the body and into an ostomy bag. In most cases, the ostomy is needed only until the anastomosis has healed, and then it can be reversed, typically after 2-6 months. The eventual reversal of the ostomy requires another operation, with a second hospital stay, recovery period and associated complications. In some cases, the ostomy may not be reversed and becomes permanent. In addition to the potential surgical complications associated with ostomy procedures, patients may experience an impact to their quality of life due to social isolation, reduced physical activity and/or intimacy. Colovac is an alternative to diverting ostomy, designed to eliminate the need for a temporary stoma in most patients. It aims to improve patient recovery and quality of life by eliminating stoma related complications including permanent stoma and eliminating the physical and emotional burden associated with stoma management and care. Colovac has been successfully studied in over 100 patients in the U.S., Europe, and Asia and has received FDA Breakthrough Designation status. 'This is a very exciting time at SafeHeal as we continue to achieve a number of critical value-creating milestones in the coming months,' said Chris Richardson, President and Chief Executive Officer. 'We are grateful for the continuing support from Sofinnova Partners and delighted to welcome Solar Eclipse, Gideon and M&L Healthcare, part of M&L Group as new investors. This capital raise places SafeHeal in an excellent position to continue our momentum toward FDA approval and commercialization of Colovac.' Chris Richardson, President & CEO, SafeHeal 'The current standard of care for treatment of Colon Resection is associated with significant morbidity, risk of permanent stoma and reduced quality of life, driving both the clinical community and regulators to search for better treatment options. SafeHeal is addressing this significant unmet medical need with a highly novel approach,' said Martin Sands of Solar Eclipse. 'I believe SafeHeal's therapeutic platform will dramatically improve quality of life and outcomes for patients with Colon Resections. I look forward to supporting the team to achieve multiple key milestones over the next 18 months.' 'We've been with SafeHeal since day one, when it was born out of our Medtech accelerator, MDStart. Our continued support in this Series C reflects a deep growing belief in their potential to revolutionize care for patients facing ostomy,' said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. ABOUT SAFEHEAL® SafeHeal SAS, headquartered in Paris, France, and its wholly owned U.S. subsidiary, SafeHeal Inc., is a clinical-stage medical device company developing Colovac, a device intended as an alternative to diverting ostomy in patients undergoing colorectal surgery. Colovac is a flexible endoluminal bypass sheath designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for 7-10 days, until the body's natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure. Colovac is an investigational device, not currently available for sale. For more information, please visit MEDIA CONTACTS USA Scott DePierro Vice President U.S. Operations and Global Business Development, SafeHeal 203-444-0279 [email protected] Europe: Karl-Heinz Blohm Vice President, International, SafeHeal +33 (0) 6 5181 7895 [email protected] ### Scott DePierro, VP US Operations & Global Business Dev SafeHeal +1 203-444-0279 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
06-05-2025
- Business
- Associated Press
SafeHeal(R) Closes Oversubscribed €35 Million Series C Equity Financing
Financing led by Solar Eclipse with new investors Gideon Strategic Partners and M&L Healthcare, part of M&L Group, and returning investors Sofinnova Partners and one of the largest Multinational life sciences corporations from a strategic standpoint. Proceeds will support the completion of SafeHeal's IDE pivotal study and preparation for commercial launch of their lead technology, Colovac®. PARIS, FRANCE AND TAMPA, FL / ACCESS Newswire / May 6, 2025 / SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced a successful completion of an oversubscribed €35 million Series C equity financing to validate the use of Colovac®, a groundbreaking temporary endoluminal fecal bypass system. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection. The proceeds leave SafeHeal well-funded to complete its IDE Pivotal study and accelerate preparation for commercial launch of their lead technology, Colovac. In conjunction with the financing, Martin Sands and Steven Sands of Solar Eclipse will join as board member and observer respectively. The Colovac endoluminal bypass system is a less-invasive alternative to temporary diverting ostomy, the current standard of care for patients undergoing colorectal resection. Diverting ostomy is applied prophylactically to most patients today undergoing a low anterior resection (LAR) and anastomosis. The ostomy temporarily diverts the stool away from the healing anastomosis to the outside of the body and into an ostomy bag. In most cases, the ostomy is needed only until the anastomosis has healed, and then it can be reversed, typically after 2-6 months. The eventual reversal of the ostomy requires another operation, with a second hospital stay, recovery period and associated complications. In some cases, the ostomy may not be reversed and becomes permanent. In addition to the potential surgical complications associated with ostomy procedures, patients may experience an impact to their quality of life due to social isolation, reduced physical activity and/or intimacy. Colovac is an alternative to diverting ostomy, designed to eliminate the need for a temporary stoma in most patients. It aims to improve patient recovery and quality of life by eliminating stoma related complications including permanent stoma and eliminating the physical and emotional burden associated with stoma management and care. Colovac has been successfully studied in over 100 patients in the U.S., Europe, and Asia and has received FDA Breakthrough Designation status. 'This is a very exciting time at SafeHeal as we continue to achieve a number of critical value-creating milestones in the coming months,' said Chris Richardson, President and Chief Executive Officer. 'We are grateful for the continuing support from Sofinnova Partners and delighted to welcome Solar Eclipse, Gideon and M&L Healthcare, part of M&L Group as new investors. This capital raise places SafeHeal in an excellent position to continue our momentum toward FDA approval and commercialization of Colovac.' Chris Richardson, President & CEO, SafeHeal 'The current standard of care for treatment of Colon Resection is associated with significant morbidity, risk of permanent stoma and reduced quality of life, driving both the clinical community and regulators to search for better treatment options. SafeHeal is addressing this significant unmet medical need with a highly novel approach,' said Martin Sands of Solar Eclipse. 'I believe SafeHeal's therapeutic platform will dramatically improve quality of life and outcomes for patients with Colon Resections. I look forward to supporting the team to achieve multiple key milestones over the next 18 months.' 'We've been with SafeHeal since day one, when it was born out of our Medtech accelerator, MDStart. Our continued support in this Series C reflects a deep growing belief in their potential to revolutionize care for patients facing ostomy,' said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. ABOUT SAFEHEAL® SafeHeal SAS, headquartered in Paris, France, and its wholly owned U.S. subsidiary, SafeHeal Inc., is a clinical-stage medical device company developing Colovac, a device intended as an alternative to diverting ostomy in patients undergoing colorectal surgery. Colovac is a flexible endoluminal bypass sheath designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for 7-10 days, until the body's natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure. Colovac is an investigational device, not currently available for sale. For more information, please visit MEDIA CONTACTS USA Scott DePierro Vice President U.S. Operations and Global Business Development, SafeHeal203-444-0279 Europe: Karl-Heinz Blohm Vice President, International, SafeHeal+33 (0) 6 5181 7895 ### SOURCE: SafeHeal press release
Newsweek
28-04-2025
- Science
- Newsweek
NASA Satellite Catches Solar Eclipse Visible Only From Space
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A solar eclipse visible only from space was captured on video thanks to a NASA satellite. On April 27, the moon blocked 23 percent of the sun in a partial eclipse, but it was not possible to see this from Earth. However, a NASA satellite recorded the eclipse from start to finish. Images from the satellite sent back to Earth first show the sun in its entirety, before a large dark orb—the moon—passes by, blocking almost a quarter of the star from view. NASA's Solar Dynamics Observatory (SDO) launched in February 2010; the semi-autonomous spacecraft points at the sun, allowing almost continuous observation. It is in a geosynchronous orbit, meaning its orbital period perfectly matches the Earth's rotation and to an earthbound stargazer appears to always remain in the same position in the sky. According to the SDO observes multiple lunar transits, or eclipses, each year—many which are not visible from Earth. An eclipse visible only from space was recorded by a NASA satellite. An eclipse visible only from space was recorded by a NASA satellite. NASA/ SDO An upcoming eclipse visible from space is due on May 25, but will cover only four percent of the sun. But another, due on July 25th, is expected to be far deeper—with more than two-thirds of the sun eclipsed by the moon at 62 percent. Stargazers across North and South America were treated to a total lunar eclipse—with the Earth moving directly between the sun and the moon—in March this year, which caused the moon to turn a deep red color. The phenomenon is known as a Blood Moon, as the same atmospheric effect that causes sunsets to appear red affects the moon. Read more What Is a Solar Eclipse? What Is a Solar Eclipse? NASA said at the time: "A lunar eclipse occurs when the Sun, Earth, and Moon align so that the Moon passes into Earth's shadow. In a total lunar eclipse, the entire Moon falls within the darkest part of Earth's shadow, called the umbra. "It's as if all the world's sunrises and sunsets are projected onto the Moon." The next solar eclipse visible from Earth will be on September 21 of this year, when the moon partially eclipses the sun. It will be visible from Australia, Antarctica, the Pacific Ocean and the Atlantic Ocean, according to NASA. A total solar eclipse will take place on August 12, 2026, but will be fully visible only in Greenland, Iceland, Spain, Russia and part of Portugal. On the same date, a partial eclipse will be visible across North America, Europe and Africa as well as the Arctic, Atlantic and Pacific oceans. Do you have a tip on a science story that Newsweek should be covering? Do you have a question about space? Let us know via science@
